Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL237100 | 0.95 | CA4 (0.84) | CA4 | |
| Citric Acid SCHEMBL5982475 | 0.95 | CA4 (0.84) | CA4 | |
| Citric Acid SCHEMBL3377726 | 0.95 | CA4 (0.84) | CA4 | |
| Citric Acid SCHEMBL9364269 | 0.95 | CA4 (0.84) | CA4 | |
| Citric Acid SCHEMBL8953955 | 0.95 | CA4 (0.84) | CA4 | |
| Citric Acid SCHEMBL29364719 | 0.95 | CA4 (0.84) | CA4 | |
| Citric Acid SCHEMBL397502 | 0.95 | CA4 (0.84) | CA4 | |
| Citric Acid SCHEMBL4086235 | 0.92 | CA4 (0.80) | CA4 | |
| Citric Acid SCHEMBL8761101 | 0.92 | CA4 (0.90) | CA4 | |
| Citric Acid SCHEMBL27616111 | 0.92 | CA4 (0.90) | CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8758817-B2 | Dosage form containing (S)-pantoprazole as active ingredient | TAKEDA GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8703192-B2 | Dosage form containing pantoprazole as active ingredient | TAKEDA GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-8465767-B2 | Mixture with tablet distegrant; sustained release; embedding water soluble particle in plastic membrane coating ; stomach disorders | TAKEDA GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| EP-1341523-B1 | PHARMACEUTICAL PREPARATION IN THE FORM OF A SUSPENSION COMPRISING AN ACID-LABILE ACTIVE INGREDIENT | NYCOMED GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2316454-B9 | Dosage form containing pantoprazole as active ingredient | NYCOMED GMBH (DE) | 2013-01-02 | — | — | EP | disclosed |
| EP-2316454-B1 | Dosage form containing pantoprazole as active ingredient | NYCOMED GMBH (DE) | 2012-09-26 | — | — | EP | disclosed |
| EP-1624870-B1 | DOSAGE FORM CONTAINING (S)-PANTOPRAZOLE AS ACTIVE INGREDIENT | NYCOMED GMBH (DE) | 2012-08-08 | — | — | EP | disclosed |
| EP-1624869-B1 | DOSAGE FORM CONTAINING PANTOPRAZOLE AS ACTIVE INGREDIENT | NYCOMED GMBH (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-1341528-B1 | RAPIDLY DISINTEGRATING TABLET COMPRISING AN ACID-LABILE ACTIVE INGREDIENT | NYCOMED GMBH (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-1746980-B1 | PHARMACEUTICAL DOSAGE FORM COMPRISING PELLETS AS WELL AS ITS MANUFACTURING PROCESS | NYCOMED GMBH (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1187601-B1 | NOVEL PREPARATION AND ADMINISTRATION FORM COMPRISING AN ACID-LABILE PROTON PUMP INHIBITOR | ALTANA PHARMA AG (DE) | 2005-07-27 | — | — | EP | disclosed |
| CN-1541091-A | Pharmaceutical prepn. in form of suspension comprising acid-labile active ingredient | ��̹��ҽҩ��˾ | 2004-10-27 | — | — | CN | disclosed |
| US-20040110661-A1 | Rapidly disintegrating tablet comprising an acid-labile active ingredient | TAKEDA GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| US-20040101558-A1 | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient | TAKEDA GMBH (DE) | 2004-05-27 | — | — | US | disclosed |
| US-20040052832-A1 | Pharmaceutical preparation in the form of a supension comprising an acid-labile active ingredient | TAKEDA GMBH (DE) | 2004-03-18 | — | — | US | disclosed |
| CN-1479613-A | rapidly disintegrating tablet containing acid-sensitive active ingredient | ��̹��ҽҩ��˾ | 2004-03-03 | — | — | CN | disclosed |
| CN-1479611-A | Pharmaceutical paste comprising acid-labile activeingredient | ��̹��ҽҩ��˾ | 2004-03-03 | — | — | CN | disclosed |
| EP-1341528-A1 | RAPIDLY DISINTEGRATING TABLET COMPRISING AN ACID-LABILE ACTIVE INGREDIENT | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| CN-1361683-A | Novel formulations and pharmaceutical forms containing an acid-labile active compound | BYK GULDEN RAUMBERG CHEMIE GMB (DE) | 2002-07-31 | — | — | CN | disclosed |
| WO-2002045694-A1 | RAPIDLY DISINTEGRATING TABLET COMPRISING AN ACID-LABILE ACTIVE INGREDIENT | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |